The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Modified FOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab beyond first progression in advanced colorectal cancer: CCOG-0801 study.
Kiyoshi Ishigure
No relevant relationships to disclose
Goro Nakayama
No relevant relationships to disclose
Keisuke Uehara
No relevant relationships to disclose
Hiroyuki Yokoyama
No relevant relationships to disclose
Akiharu Ishiyama
No relevant relationships to disclose
Takehiko Eguchi
No relevant relationships to disclose
Kenji Tsuboi
No relevant relationships to disclose
Yuichi Ando
No relevant relationships to disclose
Yasuhiro Kodera
No relevant relationships to disclose